Floatz logo

gfh375

KRAS G12D Mutation

Genfleet Therapeutics (Shanghai) Inc.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the KRAS G12D Mutation cohort.

Asset / SponsorPhaseRating
Docetaxel
Genfleet Therapeutics (Shanghai) Inc.
Phase 3B
rnk08954-01
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2CC
Arv-806
Arvinas Inc.
Phase 1/2CC

Same molecule, other indications

gfh375 is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →
malignant pancreatic neoplasmDormant
B
Indicative ·
59 / 100
View asset →
Advanced Solid Tumors CancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →